AI assistant
Sending…
Q32 Bio Inc. — Director's Dealing 2018
Mar 30, 2018
34891_dirs_2018-03-29_583507b3-ede1-424c-b353-2903936a85ae.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-03-27
Reporting Person: Gregory Richard J. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-03-27 | Employee stock option | $16.00 | A | 31160 | Acquired | 2028-03-27 | Common Stock (31160) | Direct |
Footnotes
F1: The option will vest in three equal annual installments beginning on March 27, 2019.
More from Q32 Bio Inc.
Capital/Financing Update
2026
May 27
Interim / Quarterly Report
2026
May 5
Earnings Release
2026
May 5
Annual Report
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 30
Capital/Financing Update
2026
Apr 24
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Mar 21
Director's Dealing
2026
Feb 27